Western Financial Corp CA Makes New $1.06 Million Investment in Insulet Corporation $PODD

Key Points

• Western Financial Corp CA has made a new investment of approximately $1.06 million in Insulet Corporation, purchasing 3,387 shares in the second quarter.
• Insulet reported earnings of $1.17 per share, exceeding analysts' expectations of $0.92, with a revenue of $649.10 million for the quarter.
• Several brokerages have increased their price targets on Insulet, with JPMorgan Chase raising theirs from $340 to $415, indicating a bullish outlook on the stock.

Western Financial Corp CA bought a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 3,387 shares of the medical instruments supplier's stock, valued at approximately $1,064,000.

Several other hedge funds also recently bought and sold shares of the stock. Nissay Asset Management Corp Japan ADV boosted its stake in Insulet by 0.6% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock worth $2,222,000 after buying an additional 48 shares during the period. Mather Group LLC. boosted its stake in Insulet by 4.4% during the second quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier's stock worth $360,000 after buying an additional 48 shares during the period. Brooklyn Investment Group boosted its stake in Insulet by 7.0% during the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock worth $209,000 after buying an additional 52 shares during the period. OLD National Bancorp IN boosted its stake in Insulet by 6.7% during the first quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock worth $231,000 after buying an additional 55 shares during the period. Finally, Cooper Financial Group boosted its stake in Insulet by 5.7% during the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock worth $283,000 after buying an additional 58 shares during the period.

Insulet Stock Down 1.7%

Shares of NASDAQ:PODD opened at $318.00 on Friday. The firm's 50 day moving average price is $319.01 and its 200 day moving average price is $296.63. The stock has a market cap of $22.38 billion, a price-to-earnings ratio of 96.66, a price-to-earnings-growth ratio of 2.69 and a beta of 1.36. Insulet Corporation has a fifty-two week low of $225.37 and a fifty-two week high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm's revenue was up 32.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Activity at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PODD. JPMorgan Chase & Co. increased their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research report on Friday, September 12th. The Goldman Sachs Group began coverage on shares of Insulet in a research report on Friday, May 30th. They set a "buy" rating and a $380.00 price target on the stock. Wells Fargo & Company increased their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Citigroup reissued a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Finally, Truist Financial began coverage on shares of Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 price target on the stock. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Insulet has a consensus rating of "Moderate Buy" and a consensus target price of $343.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.